June 2009
BioWorld Today;6/2/2009, Vol. 20 Issue 104, p13
The article reports on Cambridge, Massachusetts-based Mersana Therapeutics Incorporated's Phase I trial for its lead development candidate, XMT-1001. The study revealed that ten of 37 evaluable patients dosed to date showed evidence of stable disease and seven patients had prolonged stable disease for at least 12 weeks.


Related Articles

  • Clinic Roundup.  // BioWorld Today;6/24/2010, Vol. 21 Issue 121, p7 

    This section offers news briefs on drug trials. Enrollment of patients has been initiated by Anthera Pharmaceuticals Inc. in its VISTA-16 trial of varespladib A-002 drug for acute coronary syndrome. A Phase I trial was conducted by Mersana Therapeutics Inc. for its XMT-1107 anti-angiogenc...

  • Drug Trials and Older People. Witham, Miles D. // Drugs & Aging;2011, Vol. 28 Issue 8, p679 

    No abstract available.

  • From the Editor's desk. Tyrer, Peter // British Journal of Psychiatry;Mar2010, Vol. 196 Issue 3, p254 

    An introduction to the journal is presented in which the editor discusses reports published within the issue including the importance of attention to methodology in clinical trials, restriction of publication bias to drug trials, and the mental ill-effects of neglect, abuse, and deprivation.

  • National Pharmaceutical Institute answers allegations.  // Life Science Today;Feb2001, Vol. 2 Issue 1, p7 

    Reports on the Hungarian National Pharmaceutical Institute's denial that dangerous drug experiments are being carried out on unsuspecting patients. Rules concerning clinical trials in Hungary; Reasons that make Europe an easier place to find clinical trial patients.

  • ADVANCE-2: Apixaban had favorable risk-benefit profile compared with enoxaparin.  // Hem/Onc Today;8/10/2009, Vol. 10 Issue 15, p23 

    The article discusses the results of a clinical drug trial which revealed the therapeutic use of apixaban for thromboprophylaxis after total knee replacement.

  • From the Bedside to the Bedside.'.  // BioWorld Today;11/18/2009, Vol. 20 Issue 223, p7 

    This article deals with additional preliminary results reported by Mersana Therapeutics from a Phase 1 study of its lead development candidate XMT-1001 in patients with advanced solid tumors. 49 patients with refractory solid tumors served as subjects in this study. Particular focus is given to...

  • New rules for industry-sponsored articles.  // Drug Utilization Review;Oct2001, Vol. 17 Issue 10, p77 

    Discusses the rules for drug industry-sponsored articles on clinical trials enforced by the joint editorial of 12 medical journals. Reasons for implementing the rules; Details of the rules; Journals that participated in the effort.

  • Clinical trials not to be taken lightly. White, Phil // New Zealand Doctor;10/8/2008, p13 

    The author expresses his view regarding phase 3 and 4 drug trials in New Zealand, which are being promoted as a business opportunity for general practice. According to the author, these trials should not be seen as low risk as it is the first opportunity to test the drugs on humans, and it...

  • Trial Scorecards.  // Cardiology Today;Sep2013, Vol. 16 Issue 9, p12 

    This section presents a summary of the results of several clinical trials involving cardiovascular drugs, as of September 2013, including the efficacy of apixaban for treatment of thrombosis and the treatment of chronic ischemic myocardium with combined extraporporeal shock wave therapy and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics